Apr 20, 2026 09:01AM Immuneering presents genetic data supporting atebimetinib durability

Mar 9, 2026 08:05AM Immuneering Corporation (IMRX) PT Lowered to $12; Piper Sandler: 'We Remain Buyers'

Mar 6, 2026 04:39PM Oppenheimer Reiterates Outperform Rating on Immuneering Corporation (IMRX) following Q4

Jan 7, 2026 04:59PM After-hours movers: Lockheed Martin, Canadian Solar, Revolution Medicines and more

Jan 7, 2026 04:06PM Immuneering reports 64% survival rate at 12 months for pancreatic cancer drug

Nov 12, 2025 06:21PM Immuneering Corporation (IMRX) Tops Q3 EPS by 3c

Oct 31, 2025 06:08AM Leerink Partners Starts Immuneering Corporation (IMRX) at Outperform

Sep 25, 2025 09:23AM Immuneering Corporation (IMRX) PT Raised to $30 at Oppenheimer

Sep 25, 2025 06:36AM Mizuho Reiterates Outperform Rating on Immuneering Corporation (IMRX)

Sep 24, 2025 04:53PM After-hours movers: KB Home, H.B. Fuller, Hertz Global, Immuneering Corporation

Sep 24, 2025 04:01PM Immuneering reports 86% survival rate in pancreatic cancer trial

Sep 15, 2025 07:25AM Immuneering Corporation (IMRX) PT Raised to $11 at Needham

Sep 10, 2025 01:46PM Oppenheimer on Immuneering Corporation (IMRX): 'we believe there's additional upside with this upcoming catalyst'

Sep 3, 2025 06:13AM Immuneering Corporation (IMRX) files for up to 9.18M share offering by selling stockholders

Aug 25, 2025 08:02AM Immuneering secures clinical supply deal with Lilly for cancer drug combo

Aug 25, 2025 06:40AM Mizuho Reiterates Outperform Rating on Immuneering Corporation (IMRX)

Aug 13, 2025 06:01PM Immuneering Corporation (IMRX) Tops Q2 EPS by 2c

Jun 25, 2025 04:15AM Immuneering Corporation (IMRX) PT Raised to $3.50 at Jefferies

Jun 18, 2025 06:36AM Immuneering Corporation (IMRX) PT Raised to $10 at Mizuho

Jun 17, 2025 06:01AM Immuneering Corporation (IMRX) Reports Positive Overall Survival Data for Atebimetinib

May 6, 2025 04:29PM Immuneering Corporation (IMRX) Tops Q1 EPS by 5c

Mar 20, 2025 05:41PM Immuneering Corporation (IMRX) Misses Q4 EPS by 13c

Mar 20, 2025 07:00AM Immuneering Corporation (IMRX) Appoints Igor Matushansky as Chief Medical Officer

Feb 6, 2025 07:04AM Immuneering Corporation (IMRX) Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo

Jan 13, 2025 08:11AM Immuneering Corporation (IMRX) Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer

Jan 7, 2025 07:04AM Immuneering (IMRX) Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms

Dec 13, 2024 05:37AM Morgan Stanley Downgrades Immuneering Corporation (IMRX) to Underweight

Dec 12, 2024 08:00AM Immuneering Corporation (IMRX) Granted FDA Fast Track Designation for IMM-1-104

Nov 25, 2024 07:08AM Mizuho Reiterates Outperform Rating on Immuneering Corporation (IMRX)

Oct 15, 2024 08:01AM Immuneering Corporation (IMRX) Granted Orphan Drug Designation for IMM-1-104

Oct 3, 2024 06:12AM Oppenheimer Reiterates Outperform Rating on Immuneering Corporation (IMRX)

Sep 16, 2024 06:48AM Mizuho Reiterates Outperform Rating on Immuneering Corporation (IMRX)

Sep 12, 2024 04:06PM Immuneering Corporation (IMRX) Reports Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 with Chemotherapy

Aug 19, 2024 05:26AM Mizuho Reiterates Neutral Rating on Immuneering Corporation (IMRX)